Beschreibung:
<jats:title>Abstract</jats:title><jats:sec>
<jats:title>Aim</jats:title>
<jats:p>Botulinum toxin agents can improve the quality of life of patients with post-stroke upper limb spasticity (ULS) and are recommended by international and German guidelines. However, health-services research indicates an underuse of botulinum toxin agents in this patient group. The study aims to clarify the budget impact of treatment with botulinum toxin agents according to the guidelines for all eligible patients with ULS in Germany compared to usual care.</jats:p>
</jats:sec><jats:sec>
<jats:title>Methods</jats:title>
<jats:p>The budgetary impact for the statutory health insurance system was estimated by calculating a Markov cohort model with a timeframe of 5 years comparing three treatment options. Four health states were included. The base-case analysis compares standard doses of two botulinum toxin agents to usual care. The model accounts for direct medical costs. Sensitivity analyses vary doses of botulinum toxin agents and prevalence of spasticity after stroke.</jats:p>
</jats:sec><jats:sec>
<jats:title>Results</jats:title>
<jats:p>In the base case, both botulinum toxin agents lead to increased costs compared to usual care. Treatment with Dysport<jats:sup>®</jats:sup> (cumulative costs for the 5-year period: €280,321,317) is less expensive than the treatment with Xeomin<jats:sup>®</jats:sup> (€377,511,529). Cumulative costs over 5 years in usual care are €61,306,062.</jats:p>
</jats:sec><jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>The botulinum toxin therapy is associated with additional costs, but an increased use of botulinum toxin would be consistent with guideline-based therapy. In particular, it has to be considered that spasticity as a chronic condition is accompanied by a relevant loss of quality of life. Thus, considering only the therapy costs may not be sufficient for making final therapeutic decisions.</jats:p>
</jats:sec>